ProtoKinetix, Incorporated (OTCQB:PKTX)

On July 20th 2016 by OTC PR No Comments


ProtoKinetix is a bio-technology company that provides medical researchers with a platform for enhancing cell survival and health, both in vitro and in vivo.

At the heart of its technology is its patented anti-aging glycopeptide AAGP™. This small molecule (580 Daltons) displays abilities in resolving challenges confronting medical researchers in such areas as regenerative medicine and as a therapy for diseases relating to tissue inflammation and oxidation stress.

Because of its stability, small size and molecular makeup, it maintains its function in vivo without triggering the body’s immune system. Further, it can function without toxic side effects common in treatments involving larger and less stable compounds.

These abilities are verified through testing in such areas as:

  • Extension of stem cell harvesting, purification, expansion, cryopreservation and re-engraftment. See Test Results & Protocols > BioActivity Assays > “Effect of AAGP™ on Maintaining Stem Cell Number and Function in Mouse Neural Stem Cells During Cryopreservation.” Also, “Effect of AAGP™ on Preserving Cell Survival Number in Human and Mouse Neural Stem Cells During Cryopreservation.”
  • Inflammation. See Test Results & Protocols > BioActivity Assays > “AAGP™ Reduces the Inflammatory Reaction (Cox-2 Induction) in Response to an Inflammatory Stimulus (Interleukin-1B).”
  • Oxidation stress. See Test Results & Protocols > BioActivity Assays > “AAGP™ Protects Human Adult Fibroblasts Against Oxidation Stress (Hydrogen Peroxide and UVC) Induced Cell Death At 37°C.”
  • Diabetes treatment. See Test Results & Protocols > BioActivity Assays > “Affect of AAGP™ on the Functionality of Transplanted Islet Cells in a Diabetic Mouse Model.”

Additional test results can be found in the Bioactivity section.

ProtoKinetix invites university and private research researchers to examine the properties of AAGP™ to determine how it can accelerate their development of a new generation of treatments, cures, and cell-survival solutions.

It should be noted that currently there is on-going independent research in such areas as uveitis and in monoclonal-antibody production.

AAGP PresentationAAGP™ is manufactured at facilities in North America, Europe, and Asia for shipment worldwide.

Interested parties please contact us to obtain AAGP™.

ProtoKinetix’ anti-aging glycopeptide, trademarked AAGP™ is a small (580.96 Daltons), stable, synthetic replicas of the larger (>2,600 Daltons), less stable AFGP which has been found to have protective properties in nature. The small size of AAGP™ enables it to penetrate cells and allows it to pass through both cell and capillary junctions in vivo. In addition, its bioactivity at a variety of pHs (5.3-10.3) and temperatures (-196°C to 22°C) and efficiency at concentrations (1mg/ml) is well below its toxic dose (50mg/ml), making it a candidate to enter into the next stages of translational research.

AAGP™ has a chemical formula of C20H35CIF2N4O11, solubility in water of 650g.l-1, and is also soluble in methanol, ethanol and DMSO. The optimal concentration is 1-10mg/ml, depending on cell line and stress test. The optimal is pH: 5.3 – 7.3, depending on cell line and stress test.


AAGP™ has gone through a series of tests in various outsourced laboratories in Europe and North America. These tests have proven its ability to protect a multitude of cell lines (Hela cells, adult fibroblast, neonatal fibroblasts, human neuronal stem cells, mouse neuronal stem cells, mouse islet cells, blood platelets, CD34+ cells, and keratinocytes) against UVA, UVC, Hydrogen Peroxide, Inflammatory (ILβ), Time, Temperature (-196°C, -80°C, -3°C, 3°C, 4°C, 15°C and 22°C) and Low Serum induced cell death at pHs from 5.3 -10.5.

The average increase in cell survival credited to AAGP™ in the face of these conditions was over 55%. This cannot be attributed to AAGP™ increasing cell proliferation as it had been found that AAGP™ has no affect on cell doubling times in either Hela or fibroblast cells.

In addition to protecting cell survival AAGP™ also preserves cell functionality. This has been tested via stem cell markers, CD34+ functionality tests, and in vivo studies where AAGP™ treated transplanted islet cells were found to reduce blood glucose concentrations in diabetic mice by 40% by day 40 in comparison to islet cells which were transplanted into mice without first being exposed to AAGP™.


The mechanism of action of AAGP™ is now under study. However, its ability to protect against inflammation- induced cell death in exposure to hydrogen peroxide, UVA, and UVC suggests a role for AAGP™ in the inflammation pathway. In addition, when exposed to an inflammatory mediator, interleukin β (ILβ), the presence of AAGP™ reduced COX-2 expression three fold. Inflammation plays a major role in many pathological conditions suggesting AAGP™ may not just be usable in cell and organ storage but also in pharmacological treatments.

The full results of these extensive tests can be found in the ‘Test Results & Protocols’ section of the website.

AFGPs have proven useful in many applications. However, they are limited by their cost (approximately $10,000/gram), instability, and size (2,600 – 24,000 Daltons). Their large size restricts their use in medicine as they are unable to pass through capillaries into interstitial tissue and are unable to reach target cells. Molecules must be less than 600 Daltons to diffuse through the capillaries. In addition, molecules must be less than 1000 Daltons to pass through cell junctions into neighbouring cells and less than 600 Daltons to cross the blood-brain barrier.

With these issues in mind Dr. Geraldine-Castelot-Deliencourt invented AAGP™ to be a smaller, more stable synthetic version of AFGP.

Currently the most advanced independent research into AAGP™ applications is in monoclonal-antibody production and uveitis treatment.

ProtoKinetix anticipates that its future lies as a value-adding compound in two prime areas:

  • For challenges in regenerative medicine and the stresses resulting from the harvesting, purification, expansion, cryopreservation, and re-engraftment of cells.
  • For the treatment and cures of such inflammation-related conditions as diabetes, arthritis, neural-related diseases.

Accordingly, the Company encourages scientists in both university and private laboratories to view AAGP™ as a spark for new research or as an added component in on-going investigations. It welcomes inquiries and offers AAGP™ in quantities as small as one gram. For ordering information, please click here.

Leave a Reply

2019 OTC PR Group, All Rights Reserved
Menu Title